AU2018235944B2 - Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer - Google Patents

Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer Download PDF

Info

Publication number
AU2018235944B2
AU2018235944B2 AU2018235944A AU2018235944A AU2018235944B2 AU 2018235944 B2 AU2018235944 B2 AU 2018235944B2 AU 2018235944 A AU2018235944 A AU 2018235944A AU 2018235944 A AU2018235944 A AU 2018235944A AU 2018235944 B2 AU2018235944 B2 AU 2018235944B2
Authority
AU
Australia
Prior art keywords
csf
cancer
days
pfu
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018235944A
Other languages
English (en)
Other versions
AU2018235944A1 (en
Inventor
Courtney BEERS
Pedro J. Beltran
Keegan Cooke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2018235944A1 publication Critical patent/AU2018235944A1/en
Application granted granted Critical
Publication of AU2018235944B2 publication Critical patent/AU2018235944B2/en
Priority to AU2024202086A priority Critical patent/AU2024202086A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018235944A 2017-03-15 2018-03-14 Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer Active AU2018235944B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024202086A AU2024202086A1 (en) 2017-03-15 2024-04-02 Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471875P 2017-03-15 2017-03-15
US62/471,875 2017-03-15
PCT/US2018/022442 WO2018170133A1 (en) 2017-03-15 2018-03-14 Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024202086A Division AU2024202086A1 (en) 2017-03-15 2024-04-02 Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2018235944A1 AU2018235944A1 (en) 2019-09-26
AU2018235944B2 true AU2018235944B2 (en) 2024-01-04

Family

ID=61913527

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018235944A Active AU2018235944B2 (en) 2017-03-15 2018-03-14 Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
AU2024202086A Abandoned AU2024202086A1 (en) 2017-03-15 2024-04-02 Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024202086A Abandoned AU2024202086A1 (en) 2017-03-15 2024-04-02 Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer

Country Status (9)

Country Link
US (2) US20200009204A1 (cg-RX-API-DMAC10.html)
EP (1) EP3595690A1 (cg-RX-API-DMAC10.html)
JP (3) JP2020510050A (cg-RX-API-DMAC10.html)
CN (1) CN110461346A (cg-RX-API-DMAC10.html)
AU (2) AU2018235944B2 (cg-RX-API-DMAC10.html)
CA (1) CA3056392A1 (cg-RX-API-DMAC10.html)
MA (1) MA51630A (cg-RX-API-DMAC10.html)
MX (3) MX2019010797A (cg-RX-API-DMAC10.html)
WO (1) WO2018170133A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201590451A1 (ru) * 2012-08-30 2016-05-31 Эмджен Инк. Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки
CA3071599A1 (en) * 2017-08-07 2019-02-14 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
CN116870165A (zh) * 2018-08-17 2023-10-13 北京奥源和力生物技术有限公司 用于治疗癌症的组合及其治疗用途
CN116802278A (zh) * 2020-09-18 2023-09-22 成都美杰赛尔生物科技有限公司 溶瘤病毒与经改造的免疫细胞联合治疗肿瘤
US20240299540A1 (en) 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
JP7697147B2 (ja) 2021-06-03 2025-06-23 上▲海▼允英生物医▲薬▼科技有限公司 腫瘍溶解性ウイルスベクターおよびその適用
TW202321458A (zh) * 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
CN117653676A (zh) * 2022-08-22 2024-03-08 上海长征医院 溶瘤病毒vg161与免疫检查点抑制剂在制备治疗骨与软组织肿瘤药物中的应用
US12129634B2 (en) * 2022-08-23 2024-10-29 Vetta, Llc Sink system
CN115463161A (zh) * 2022-09-15 2022-12-13 广东天普生化医药股份有限公司 一种溶瘤病毒在制备治疗骨肉瘤的药物组合物中的应用
CN116271052B (zh) * 2022-11-11 2025-07-04 上海市普陀区中心医院 溶瘤病毒vg161或与免疫检查点抑制剂联用在治疗胃癌中的应用
CN121335710A (zh) * 2023-04-07 2026-01-13 上海复诺健生物科技有限公司 重组溶瘤病毒与检查点抑制剂的组合用于治疗癌症
CN120648657A (zh) * 2024-03-08 2025-09-16 上海锦斯生物技术有限公司 一种修饰的溶瘤病毒及其组合物
CN119524123A (zh) * 2024-11-08 2025-02-28 北京肿瘤医院(北京大学肿瘤医院) 溶瘤病毒联合pd-1单抗在制备黑色素瘤治疗药物中的应用
CN119792537B (zh) * 2025-01-22 2025-10-21 常州大学 利巴韦林与pd-1抑制剂联合用药物组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036412A2 (en) * 2012-08-30 2014-03-06 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
WO2016009017A1 (en) * 2014-07-16 2016-01-21 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
JP2003535565A (ja) 1998-12-31 2003-12-02 アーチ ディベロプメント コーポレイション 新生物疾患の治療に有用な組換え単純ヘルペスウイルス
AU2905199A (en) 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP4810042B2 (ja) 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
CN1286303A (zh) 2000-08-17 2001-03-07 上海市农业科学院生物技术研究中心 抗人龋齿致病菌蛋白基因及其制备方法
EP1381280B1 (en) 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
ES2704632T3 (es) 2011-09-08 2019-03-19 Univ New York Virus de herpes simplex oncolítico y sus usos terapéuticos
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
EP3217993A1 (en) * 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
US20190022203A1 (en) * 2016-01-11 2019-01-24 Turnstone Limited Partnership Oncolytic virus and checkpoint inhibitor combination therapy
US11497781B2 (en) * 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
EP3225253A1 (en) * 2016-04-01 2017-10-04 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
JP2020501589A (ja) * 2016-12-23 2020-01-23 ウイルツ・バイオロジクス・リミテッド がんの治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014036412A2 (en) * 2012-08-30 2014-03-06 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
WO2016009017A1 (en) * 2014-07-16 2016-01-21 Institut Gustave-Roussy Combination of oncolytic virus with immune checkpoint modulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials.gov - NCT02978625, (2016-12-01), https://clinicaltrials.gov/ct2/show/NCT02978625. *
Fukuhara, H.et al., 'Oncolytic virus therapy: A new era of cancer treatment at dawn', Cancer Science, (2016-09-09), vol. 107, no. 10, pages 1373 - 1379, doi: 10.1111/cas.13027. *
Liu, B et al., 'ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties', Gene Therapy, (2003-02-01), vol. 10, no. 4, pages 292 - 303, doi: 10.1038/SJ.GT.3301885. *
Prescribing information for IMLYGIC® from the United States FDA, (2015-10-01), Retrieved from the Internet :https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM469575.pdf. *

Also Published As

Publication number Publication date
JP2023089171A (ja) 2023-06-27
WO2018170133A1 (en) 2018-09-20
MX2024006614A (es) 2024-06-19
JP7654708B2 (ja) 2025-04-01
MX2019010797A (es) 2019-10-24
EP3595690A1 (en) 2020-01-22
AU2024202086A1 (en) 2024-04-18
MX2025001102A (es) 2025-03-07
MA51630A (fr) 2020-01-22
US20260102446A1 (en) 2026-04-16
JP2020510050A (ja) 2020-04-02
US20200009204A1 (en) 2020-01-09
AU2018235944A1 (en) 2019-09-26
JP7869895B2 (ja) 2026-06-03
JP2025094078A (ja) 2025-06-24
CN110461346A (zh) 2019-11-15
CA3056392A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
US20260102446A1 (en) Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
US20230330182A1 (en) Combined preparations for the treatment of cancer or infection
Guidi et al. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review
US11446377B2 (en) Anti-B7-H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer
US20200078426A1 (en) Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
TWI851676B (zh) 溶瘤病毒用於治療癌症之用途
AU2017207532A1 (en) Oncolytic virus and checkpoint inhibitor combination therapy
TW202102543A (zh) 溶瘤病毒在癌症新輔助療法中之用途
WO2018075447A1 (en) Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
US20190083556A1 (en) Analytical methods and arrays for use in the same
HK40067473A (en) Combined preparations for the treatment of cancer or infection
HK40006950A (en) Combined preparations for the treatment of cancer or infection
HK40006950B (en) Combined preparations for the treatment of cancer
EA050675B1 (ru) Применение онколитических вирусов для лечения рака
HK1239550B (en) Combined preparations for the treatment of cancer or infection
HK1239550A1 (en) Combined preparations for the treatment of cancer or infection

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)